These cytokines play a significant role in the degradation of β‐cells.[13, 14] Hence, therapeutic strategies aimed at modulating autoreactive lymphocytes show considerable potential in addressing T1D.[15, 16, 17] Notably, CD3 targeted depletion of pancreatic antigen‐specific autoreactive T cells using agents like teplizumab has been shown to enhance sustained insulin production in recently diagnosed individuals.[18, 19] Nevertheless, concerns persist regarding the safety and effectiveness of this non‐antigen‐specific intervention. Here, INS is linked to type 1 diabetes mellitus.